Disc Medicine, Inc.
Disc Medicine is a clinical-stage biopharmaceutical company developing treatments for patients with serious hematologic diseases. Its product candidates target biological pathways involved in red blood cell formation and function, particularly heme biosynthesis and iron homeostasis. Bitopertin is being developed for erythropoietic porphyrias, including EPP and XLP. The iron homeostasis portfolio includes DISC-0974, in clinical development for anemia of myelofibrosis and anemia associated with inflammatory bowel disease; DISC-3405, being developed for polycythemia vera, sickle cell disease and other hematologic disorders; and preclinical candidate DISC-0998 for anemia associated with inflammatory diseases. Disc Medicine develops its candidates through internal research and licenses from other companies, and aims to commercialize them if approved. It holds exclusive worldwide development and commercialization licenses for bitopertin, DISC-0974 and DISC-0998, and rights to DISC-3405 and related antibodies outside Greater China and Southeast Asia. Disc Medicine is headquartered in Watertown, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Guggenheim initiated coverage on Disc Medicine (NASDAQ: IRON) with a buy rating and a $132 price target, citing its pipeline for blood disorders. The firm projects over $3B in peak sales. IRON's stock rose 39% post-Phase 3 trial results, with a market cap of $3.59B. Analysts highlight upcoming milestones as potential catalysts.
Disc Medicine reported Q3 GAAP EPS of -$1.53, beating estimates by $0.20. The company had $683M in cash and equivalents, and raised $486M in a public offering in October 2026, extending its cash runway.
Disc Medicine, Inc. (IRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update • Pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints • Bitopertin NDA resubmission planned by e
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning IRON (Disc Medicine, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent IRON coverage spans financial news, earnings and insider activity.
In the last 30 days, IRON insiders filed 9 SEC Form 4 transactions — no purchases and 9 sales ($3.4M). The most active reporter was Bitterman Kevin with 9 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst initiation and buy rating suggest upside potential.
Earnings beat and strong cash position suggest upside potential.
Positive pivotal trial results and a planned NDA resubmission are likely to drive the stock higher.
The large equity raise will likely dilute existing shareholders and put short‑term pressure on the stock, though proceeds fund pipeline development.
The insider sale may signal modest downside pressure as the market prices in the director's reduced holding.
AlphAI scores every news story that mentions IRON with an AI model for sentiment and relevance, and aggregates insider trades from Disc Medicine, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Guggenheim initiated coverage on Disc Medicine (NASDAQ: IRON) with a buy rating and a $132 price target, citing its pipeline for blood disorders. The firm projects over $3B in peak sales. IRON's stock rose 39% post-Phase 3 trial results, with a market cap of $3.59B. Analysts highlight upcoming milestones as potential catalysts.
Disc Medicine reported Q3 GAAP EPS of -$1.53, beating estimates by $0.20. The company had $683M in cash and equivalents, and raised $486M in a public offering in October 2026, extending its cash runway.
Disc Medicine, Inc. (IRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update • Pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints • Bitopertin NDA resubmission planned by e
Disc Medicine, Inc. (IRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants October 19, 2026 WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on
Bitterman Kevin sold 41,825 indirectly-held shares of Disc Medicine, Inc. (IRON) at an average of $80.13 ($79.95–$80.23, $3.35M total) across 9 trades over 2026-10-19 to 2026-10-21 under a Rule 10b5-1 trading plan.
Jefferies raised its price target for Disc Medicine (NASDAQ:IRON) to $149 from $128, citing positive Phase 3 results for bitopertin. The stock has surged 42.6% in a week. Multiple analysts have raised targets, with estimates for a $1B-$2B commercial opportunity. Disc Medicine plans to provide regulatory updates by year-end 2026.
Disc Medicine, Inc. (IRON) priced a $450M stock offering at $75 per share, selling 6M shares with an option for 900,000 more. Closing is expected Oct. 22, 2026, subject to conditions. According to the company, proceeds will support potential commercialization efforts.
Wells Fargo maintained an Overweight rating on Disc Medicine Inc (IRON) and raised its price target to $124 from $86, citing growth potential in its clinical-stage biopharmaceutical pipeline. The company has a market cap of $3.03 billion but faces profitability challenges, with a GF Score of 35. Insider activity shows over $10 million in sells in the last three months.
Truist Securities raised its price target for Disc Medicine (NASDAQ:IRON) to $115 from $83, maintaining a Buy rating. The stock surged 39% in the past week to $78.90. The firm cited confidence in the regulatory and commercial outlook for bitopertin following positive APOLLO trial results. Disc Medicine expects to resubmit its application by the end of 2026, with a potential FDA decision in mid-2027. Other analysts also raised price targets following the trial data.
Disc Medicine's Phase 3 trial for a rare light-sensitivity disorder met all endpoints, shares rose 38.86%. Silence Therapeutics agreed to a $1.3B acquisition by Merck KGaA at a 130% premium, shares up 125.58%. Other rare blood disorder-focused companies also saw gains. Disc plans FDA resubmission by 2026 end, Silence deal expected Q1 2027.
